5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

4. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Biotechnology Value Fund’s Stake Value: $168 million

Percentage of Biotechnology Value Fund’s 13F Portfolio: 6.31% 

Number of Hedge Fund Holders: 27

The developer of peptide-based therapeutic drugs, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the top pharma stocks to buy because of a staggering share price gain since the beginning of this year. Its stock price is up almost 50% year to date.